AstraZeneca stock heads into the open after a 3.0% London gain

AstraZeneca stock closed at GBP 120.62 on the London Stock Exchange on September 14, 2026, up 3.0% for the session. In the same session the FTSE 100 index rose 0.66%, so AstraZeneca outperformed its home benchmark by more than 2 percentage points.

September 14, 2026 in numbers

AstraZeneca PLC (ISIN GB0009895292) saw its shares trade between an intraday high of GBP 120.66 and levels close to the closing price on September 14, 2026 in London, with the move marking a clear advance within the recent range per market data. The 3.0% gain contrasted with the FTSE 100 close at 10,720.22, up 0.66% on the day, indicating stronger demand for AstraZeneca relative to the broader UK large cap index, according to closing figures reported for the FTSE 100 by RTTNews. The session followed news that AstraZeneca’s breast cancer pill camizestrant, sold as Etcamah, did not achieve a statistically significant improvement in progression free survival in a late stage trial when combined with Pfizer’s Palbociclib, a setback that analysts estimate could trim several billion dollars from the drug’s potential sales, as discussed by CNBC and Bloomberg. Despite the trial disappointment, investors focused on the broader pharmaceutical strength that supported the UK market, with AstraZeneca among the notable gainers highlighted by RTTNews.

Today’s drivers and events

Today, AstraZeneca enters the new session with the recent breast cancer trial outcome still shaping sentiment, as market reports from CNBC and commentary on the potential revenue impact from Bloomberg continue to frame expectations around the company’s oncology pipeline. Broader moves in European pharmaceuticals and any further analyst updates following the Etcamah data could influence AstraZeneca shares today, alongside the general direction of the FTSE 100, which recently benefited from strength in pharma and energy, according to RTTNews.